Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Chardan Capital in a research note issued on Tuesday, Benzinga reports. They currently have a $30.00 price objective on the stock. Sonnet BioTherapeutics Stock Up 1.9 % Shares of Sonnet BioTherapeutics stock opened at $1.65 on Tuesday. The firm’s […]
PRINCETON, NJ / ACCESSWIRE / May 22, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced
Sonnet BioTherapeutics Announces Review of Strategic Alternatives pr-inside.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr-inside.com Daily Mail and Mail on Sunday newspapers.
OPENING CALL Stock futures were little changed on Tuesday with consumer spending in focus, as a slew of earnings from retailers were due. Expected results from Lowe's, Macy's, AutoZone and... -May 21, 2024 at 06:22 am EDT
- MarketScreener
North American Morning Briefing: Stock Futures Flat Ahead of Retail Earnings morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target ...
The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levelsPatients have received up to 25 cycles of SON-1010 as monotherapy and 10
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 ... pr-inside.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr-inside.com Daily Mail and Mail on Sunday newspapers.
Sonnet BioTherapeutics (SONN) Reports Updated Clinical Data for SON-1010 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.